[go: up one dir, main page]

EA200870029A1 - Способ применения антагонистов il-6 с ингибиторами протеасом - Google Patents

Способ применения антагонистов il-6 с ингибиторами протеасом

Info

Publication number
EA200870029A1
EA200870029A1 EA200870029A EA200870029A EA200870029A1 EA 200870029 A1 EA200870029 A1 EA 200870029A1 EA 200870029 A EA200870029 A EA 200870029A EA 200870029 A EA200870029 A EA 200870029A EA 200870029 A1 EA200870029 A1 EA 200870029A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
application
proteas
inhibitors
proteas inhibitors
Prior art date
Application number
EA200870029A
Other languages
English (en)
Other versions
EA014675B1 (ru
Inventor
Мохамед Заки
Джеффри Немет
Роберт Орловски
Original Assignee
Сентокор, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сентокор, Инк. filed Critical Сентокор, Инк.
Publication of EA200870029A1 publication Critical patent/EA200870029A1/ru
Publication of EA014675B1 publication Critical patent/EA014675B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение относится к способу лечения ракового заболевания или связанного с IL-6 нарушения или состояния у млекопитающего, включающему совместное введение ингибитора протеасом с антагонистом IL-6.
EA200870029A 2005-12-09 2006-12-08 Способ применения антагонистов il-6 с ингибиторами протеасом EA014675B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74915205P 2005-12-09 2005-12-09
PCT/US2006/061786 WO2007067976A2 (en) 2005-12-09 2006-12-08 Method of using il6 antagonists with proteasome inhibitors

Publications (2)

Publication Number Publication Date
EA200870029A1 true EA200870029A1 (ru) 2008-10-30
EA014675B1 EA014675B1 (ru) 2010-12-30

Family

ID=38123650

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870029A EA014675B1 (ru) 2005-12-09 2006-12-08 Способ применения антагонистов il-6 с ингибиторами протеасом

Country Status (15)

Country Link
US (1) US20090022726A1 (ru)
EP (1) EP1954310A4 (ru)
JP (1) JP2009518447A (ru)
KR (1) KR20080072761A (ru)
CN (1) CN101325969A (ru)
AR (1) AR057227A1 (ru)
AU (1) AU2006321610A1 (ru)
BR (1) BRPI0619498A2 (ru)
CA (1) CA2632732A1 (ru)
EA (1) EA014675B1 (ru)
IL (1) IL191694A0 (ru)
NO (1) NO20082907L (ru)
TW (1) TW200803895A (ru)
WO (1) WO2007067976A2 (ru)
ZA (1) ZA200805956B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2676078C2 (ru) * 2012-05-23 2018-12-26 Ардженкс Бвба Молекулы, связывающие il-6

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
DK1745064T3 (da) 2004-04-15 2011-04-11 Proteolix Inc Forbindelser til proteasomenzyminhibering
US8088741B2 (en) 2004-05-10 2012-01-03 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
WO2007046489A1 (ja) 2005-10-21 2007-04-26 Chugai Seiyaku Kabushiki Kaisha 心疾患治療剤
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
AR057582A1 (es) * 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
ES2685915T3 (es) * 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
CN101495146B (zh) 2006-04-07 2012-10-17 国立大学法人大阪大学 肌肉再生促进剂
UA101303C2 (ru) 2006-06-19 2013-03-25 Протеолікс, Інк. Соединения для ингибирования фермента протеасомы
ES2564392T3 (es) * 2007-01-23 2016-03-22 Shinshu University Inhibidores de IL-6 para el tratamiento de rechazo crónico
JP5424330B2 (ja) * 2007-07-26 2014-02-26 国立大学法人大阪大学 インターロイキン６受容体阻害剤を有効成分とする眼炎症疾患治療剤
ES2684340T3 (es) 2007-10-04 2018-10-02 Onyx Therapeutics, Inc. Inhibidores de proteasa epoxi cetona de péptidos cristalinos y síntesis de cetoepóxidos de aminoácidos
JP5544290B2 (ja) * 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
EP2344165A4 (en) * 2008-10-01 2012-12-05 Reddys Lab Ltd Dr PHARMACEUTICAL COMPOSITIONS COMPRISING BORONIC ACID COMPOUNDS
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
EP2355828B1 (en) 2008-11-13 2018-05-30 Gilead Calistoga LLC Therapies for hematologic malignancies
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2464666B1 (en) 2009-07-15 2018-03-21 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
AU2010278067B2 (en) * 2009-07-31 2016-10-27 Shin Maeda Cancer metastasis inhibitor
US7947653B1 (en) 2009-10-09 2011-05-24 Cold Spring Harbor Laboratory Methods for treating epidermal growth factor receptor tyrosine kinase inhibitor-resistant cancers
US8323883B1 (en) 2009-10-09 2012-12-04 Cold Spring Harbor Laboratory Methods of assessing therapeutic benefits of patients having cancers resistant to epidermal growth factor receptor kinase inhibitors
JP5919196B2 (ja) * 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
CA2791651C (en) 2010-03-01 2019-08-20 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
US20140294854A1 (en) * 2011-03-10 2014-10-02 Albert Einstein College Of Medicine Of Yeshiva University Target directed to adipocytes, methods and assays for treatment of obesity
WO2014011695A2 (en) 2012-07-09 2014-01-16 Onyx Therapeutics, Inc. Prodrugs of peptide epoxy ketone protease inhibitors
KR101643041B1 (ko) * 2014-04-25 2016-07-28 아주대학교산학협력단 프로테아좀 저해제 및 디히드로피리딘계 화합물을 유효성분으로 함유하는 암의 예방 또는 치료용 조성물
CN104922659B (zh) * 2015-07-03 2018-04-20 刘永庆 防治肿瘤和/或慢性结核病的Th2免疫反应抑制剂及其应用
WO2017138008A2 (en) * 2016-02-14 2017-08-17 Yeda Research And Development Co. Ltd. Methods of modulating protein exocytosis and uses of same in therapy
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US20200246488A1 (en) * 2017-07-17 2020-08-06 The Broad Institute, Inc. Compositions and methods for treating inflammatory bowel diseases
EP3698808B1 (en) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
US20200165608A1 (en) * 2018-11-23 2020-05-28 Florida State University Research Foundation, Inc. Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210075A (en) * 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
US5340736A (en) * 1991-05-13 1994-08-23 The President & Fellows Of Harvard College ATP-dependent protease and use of inhibitors for same in the treatment of cachexia and muscle wasting
TW458985B (en) * 1993-05-31 2001-10-11 Chugai Pharmaceutical Co Ltd Reconstructed human antibody against human interleukin-6
US5888510A (en) * 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
CN1331752A (zh) * 1998-10-20 2002-01-16 千年药物公司 监测蛋白酶体抑制剂药物作用的方法
RU2318829C2 (ru) * 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
AU2004210626A1 (en) * 2003-02-04 2004-08-26 Centocor Inc. Use of IL-6 antagonists in combination with steroids to enhance apoptosis
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2676078C2 (ru) * 2012-05-23 2018-12-26 Ардженкс Бвба Молекулы, связывающие il-6

Also Published As

Publication number Publication date
WO2007067976A2 (en) 2007-06-14
CA2632732A1 (en) 2007-06-14
CN101325969A (zh) 2008-12-17
EA014675B1 (ru) 2010-12-30
NO20082907L (no) 2008-08-26
KR20080072761A (ko) 2008-08-06
AU2006321610A1 (en) 2007-06-14
EP1954310A2 (en) 2008-08-13
BRPI0619498A2 (pt) 2011-10-04
ZA200805956B (en) 2009-10-28
US20090022726A1 (en) 2009-01-22
EP1954310A4 (en) 2009-04-22
AR057227A1 (es) 2007-11-21
IL191694A0 (en) 2008-12-29
TW200803895A (en) 2008-01-16
WO2007067976A3 (en) 2008-02-14
JP2009518447A (ja) 2009-05-07

Similar Documents

Publication Publication Date Title
EA200870029A1 (ru) Способ применения антагонистов il-6 с ингибиторами протеасом
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
EA200870409A1 (ru) Антагонисты киназы pi3
HUS1400007I1 (hu) Dipeptidil-peptidáz inhibitorok
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
CR9874A (es) Dipeptidyl peptidase inhibitors for treating diabetes
DE602004010206D1 (de) Dipeptidyl Peptidase Inhibitoren.
ECSP088959A (es) Inhibidores heterocíclicos de aspartil-proteasa
NO20065148L (no) Monocykliske heterocykler som kinase inhibitorer
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
ATE526325T1 (de) Substituierte benzimidazole als kinaseinhibitoren
NO20071309L (no) Fremgangsmate for ekspansjon
NO20071127L (no) Triazoloftalaziner
EA200701396A1 (ru) Триазолофталазины в качестве ингибиторов pde-2
DK1761520T3 (da) Kinaseinhibitorer
ATE554769T1 (de) Neuromuskuläre blocker mit mittlerer dauer und antagonisten advon
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
DE602007007664D1 (de) Renininhibitoren
WO2006057997A3 (en) Plasmin-inhibitory therapies
EP1758585A4 (en) HIV integrase
ATE512967T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU